U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07835035) titled 'Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy' on Sept. 10.
Brief Summary: This multicenter, open-label, single-arm exploratory study will evaluate the safety, tolerability, and preliminary antitumor activity of rimegepant in combination with toripalimab in patients with locally advanced or metastatic urothelial carcinoma after failure of prior standard therapy. Approximately 6 to 12 participants will be enrolled. The primary objectives are to assess dose-limiting toxicities and other safety outcomes and to determine the recommended Phase 2 dose (RP2D) of rimegepant when combined wit...